Crystagen

1. Overview

Crystagen (also spelled Kristagen, designated T-38) is a synthetic tripeptide with the amino acid sequence Glu-Asp-Pro (EDP) and an approximate molecular weight of 345 g/mol, developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology as an immune system bioregulator [1][2][8]. It holds a unique position among Khavinson peptides as one of three principal bioactive components identified within Thymalin, a bovine thymus extract that has been approved for clinical use in Russia since 1982 [2][10].

Thymalin was isolated from calf thymus tissue in the 1970s by Khavinson and Vyacheslav Morozov. Subsequent analysis via reversed-phase HPLC identified three short peptides with high biological activity: the dipeptide L-Glu-L-Trp (EW, later synthesized as Thymogen), the dipeptide Lys-Glu (KE, marketed as Vilon), and the tripeptide Glu-Asp-Pro (EDP, marketed as Crystagen) [2]. Crystagen therefore represents the synthetic reproduction of one specific active fraction from a clinically used biological extract.

Crystagen's mechanism centers on immune regulation through T-cell and B-cell modulation, thymic epithelial cell proliferation, and cytokine network modulation. It has demonstrated immunoprotective effects in aging spleen tissue and selective enhancement of normal lymphocyte proliferation while inhibiting tumor cell growth [1][2][6].

Molecular Weight

~345 g/mol

Sequence

Glu-Asp-Pro (EDP)

Peptide Type

Synthetic tripeptide bioregulator (Khavinson class); active component of Thymalin

Source

Identified from bovine thymus extract (Thymalin) via reversed-phase HPLC

Mechanism

T-cell and B-cell immune regulation; thymic epithelial cell proliferation; cytokine modulation (IL-1, IL-6, TNF-alpha); lymphocyte proliferative activity enhancement

Routes Studied

Oral (capsules), sublingual, subcutaneous (preclinical)

FDA Status

Not approved; not evaluated by any Western regulatory agency

WADA Status

Not specifically listed; falls under S0 (Non-Approved Substances)

2. Mechanism of Action

Crystagen operates through multiple immunomodulatory pathways, with particular emphasis on thymic function maintenance and immune cell regulation.

B-Cell and T-Cell Regulation

In organotypic spleen tissue cultures from aging rats, Crystagen (EDP) was found to activate B-cells of the immune system [1]. Notably, in comparative studies with other thymus-derived peptides, Crystagen showed a distinct mechanism: while Vilon (KE) activated T-helpers by decreasing apoptosis, and R-1 peptide activated T-helpers by increasing proliferation and differentiation, Crystagen primarily stimulated the B-cell compartment [1].

In clinical observational data, Crystagen demonstrated effects on T-cell immunity as well, increasing CD3+ and CD4+ cell numbers and normalizing the CD4+/CD8+ ratio [2][11]. Immunogram normalization was achieved in 82% of patients versus 56% in controls receiving standard treatment [2].

Thymic Epithelial Cell Proliferation

EDP activates proliferation of VTEC2.H/S human thymic epithelial cells [2]. These cells form the thymic microenvironment essential for T-cell maturation and selection. By supporting thymic epithelial function, Crystagen may counteract age-related thymic involution -- the progressive replacement of functional thymic tissue with adipose tissue that begins at puberty and is largely complete by age 60-70.

Selective Immune Cell Effects

A particularly notable property of Crystagen is its differential effect on normal versus malignant cells. EDP enhances spontaneous proliferative activity of normal human lymphocytes while simultaneously inhibiting proliferation of K-562 human erythromyelosis tumor cells [2]. This selectivity -- stimulating normal immune cells while suppressing tumor cell growth -- is unusual among immunomodulatory agents and is shared with its parent compound Thymalin.

Cytokine Modulation

EDP shows stimulatory effects on peritoneal macrophage cytokine secretion, including IL-1, IL-6, and TNF-alpha, in both young and old mice [2][3]. In the THP-1 monocyte/macrophage cell line, EDP and other thymus-derived peptides regulated the balance between pro-inflammatory and anti-inflammatory cytokine expression [3]. This dual cytokine-modulating effect suggests immunoregulatory rather than purely immunostimulatory activity.

Thymic Radioprotection

In gamma-irradiated rats, Crystagen treatment preserved the cortex-medulla architectural division of the thymus, increased numbers of macrophages and mast cells, and maintained thymocyte proliferation [2]. This radioprotective effect on thymic tissue is consistent with Crystagen's origin as a thymus-specific bioregulator and has implications for immune reconstitution following radiation exposure.

DNA and Histone Interaction

Like other Khavinson peptides, EDP is proposed to penetrate cell nuclei and interact with DNA and histone proteins [4][14]. The tripeptide regulates gene expression involved in heat shock protein synthesis, cytokine production, fibrinolysis, and differentiation of immune cells [2][4]. These interactions are proposed to occur through direct binding to specific DNA sequences and chromatin structural proteins, modulating transcriptional accessibility.

3. Researched Applications

Immune Reconstitution in Aging

Evidence level: Limited clinical (observational), preclinical

The primary application of Crystagen involves age-related immune decline (immunosenescence). By stimulating both T-cell and B-cell populations, supporting thymic epithelial function, and modulating cytokine networks, Crystagen addresses multiple aspects of immune aging [1][2][9]. Clinical observational data report immunogram normalization in 82% of elderly patients, with increases in CD3+, CD4+ cell counts and normalization of the CD4+/CD8+ ratio [2][11].

These findings are contextualized by the broader Thymalin clinical dataset: the parent preparation containing EDP reduced mortality 2.0-2.1-fold in elderly subjects over 6-8 years of follow-up [5]. However, attributing Thymalin's clinical effects specifically to EDP is complicated by the multi-component nature of the extract.

Post-Radiation Immune Recovery

Evidence level: Preclinical (animal study)

Crystagen's thymic radioprotective effects suggest application in immune reconstitution following radiation exposure, whether from radiotherapy, nuclear accidents, or occupational exposure. The preservation of thymic architecture and thymocyte proliferation in irradiated animals supports this potential application [2].

Anti-Tumor Immune Modulation

Evidence level: Preclinical (in vitro)

The selective stimulation of normal lymphocyte proliferation while inhibiting K-562 tumor cell growth positions Crystagen as a potential immune adjuvant in cancer therapy [2]. This selectivity parallels findings with the full Thymalin extract and the synthetic EW dipeptide, both of which have demonstrated anti-tumor effects in animal models [12].

General Immunodeficiency

Evidence level: Limited clinical (observational)

In Russian clinical practice, Crystagen has been used for general immune support in the context of recurrent infections, post-surgical immune recovery, and age-related immune decline [2][11]. These applications derive from the broader Thymalin/bioregulator clinical framework rather than from Crystagen-specific controlled trials.

4. Clinical Evidence Summary

5. Dosing in Research

The following table summarizes doses used in published research studies. These are not therapeutic recommendations. Crystagen is not approved for human use by the FDA, EMA, or other major Western regulatory agencies.

Commonly Referenced Protocols

In the Khavinson bioregulator system, Crystagen is available as oral capsules at 200-400 mcg per dose, taken for courses of 10-30 days and repeated 2-3 times annually. This dosing derives from the Russian peptide supplement framework. For more intensive immune support, the parent preparation Thymalin is administered intramuscularly at 10 mg daily for 5-10 days, with courses repeated annually [2][16].

6. Safety and Side Effects

Published Safety Data

No adverse effects attributable to Crystagen have been reported in published studies. The parent preparation Thymalin has been described as "practically non-toxic" based on over 40 years of clinical use in Russia [2][10].

In the COVID-19 RCT with Thymalin (which contains EDP), no adverse events were documented in the treatment group [16]. The long-term observational studies with Thymalin in elderly populations similarly reported no significant safety concerns [5].

As a tripeptide composed of common L-amino acids (glutamic acid, aspartic acid, proline), Crystagen is expected to be rapidly metabolized by endogenous peptidases.

Critical Safety Gaps

• No formal toxicology studies specific to the isolated EDP tripeptide
• No dose-escalation or maximum tolerated dose studies
• No pharmacokinetic studies
• No drug interaction studies, particularly with immunosuppressants, vaccines, or other immunomodulators
• No safety assessment in autoimmune conditions (immunostimulation could theoretically exacerbate autoimmunity)
• No evaluation in organ transplant recipients
• All safety data originate from Khavinson's research group or affiliated institutions

Immunostimulation Considerations

As an immunostimulatory agent, Crystagen's use in patients with autoimmune conditions, organ transplants, or active malignancies requires careful consideration. Stimulation of immune cell populations could theoretically worsen autoimmune flares, accelerate graft rejection, or produce unpredictable effects in the setting of immunotherapy.

7. Comparison with Related Peptides

Crystagen (EDP) vs. Thymalin (Extract)

Crystagen is one of three identified active components of Thymalin. While Thymalin has the most extensive clinical dataset among Khavinson preparations (including the COVID-19 RCT and longevity observational studies), its multi-component nature makes it difficult to attribute effects to specific peptides. Crystagen represents an attempt to isolate one specific immunomodulatory fraction.

Crystagen (EDP) vs. Thymogen (EW dipeptide)

Both are synthetic peptides derived from Thymalin. Thymogen (Glu-Trp) is a dipeptide with separate regulatory approval in Russia and more extensive independent characterization. It primarily enhances T-cell differentiation and neutrophil function through cyclic nucleotide modulation [10]. Crystagen (EDP) appears to have broader immune effects, activating both B-cells and T-cells.

Crystagen (EDP) vs. Thymosin Alpha-1

Thymosin alpha-1 is a 28-amino acid peptide with established receptor-mediated signaling (TLR2, TLR9) and approval in over 35 countries. It represents the most clinically validated thymic peptide globally, with extensive independent clinical trial data [2]. Crystagen, at only 3 amino acids, proposes a fundamentally different mechanism (direct nuclear DNA binding) and has far less independent validation.

Crystagen (EDP) vs. Chonluten (EDG)

Both are tripeptides sharing the Glu-Asp core, differing only in the third amino acid (Pro vs. Gly). This single amino acid change determines tissue specificity: Crystagen targets the immune/thymic system while Chonluten targets bronchial mucosa. Both demonstrate anti-inflammatory properties but in their respective target tissues.

8. Relationship to Thymalin

Crystagen occupies a distinctive position in the Khavinson peptide family because its parent compound, Thymalin, has the most extensive clinical history of any Khavinson bioregulator -- approved in the USSR/Russia since 1982 and used in clinical settings for over four decades [2][10]. The identification of EDP as a principal active component of Thymalin provides Crystagen with an indirect clinical pedigree that other synthetic Khavinson peptides lack.

However, this relationship also introduces complexity. The clinical effects observed with Thymalin (mortality reduction, COVID-19 outcomes, immune reconstitution) cannot be definitively attributed to EDP alone, as the extract contains the EW dipeptide, KE dipeptide, and potentially other unidentified bioactive fractions [2]. Whether the isolated tripeptide reproduces the full spectrum of Thymalin's clinical effects remains unproven.

9. Limitations and Transparency

Key limitations of the Crystagen evidence base:

• All research originates from Khavinson's institute and affiliated laboratories
• No independent replication by Western research groups
• The most compelling clinical data derives from the multi-component Thymalin extract, not isolated Crystagen
• No randomized, controlled clinical trials with isolated EDP have been published
• The proposed mechanism (direct peptide-DNA binding for gene regulation) remains controversial
• Tripeptide stability and oral bioavailability are fundamental pharmacokinetic concerns
• Commercial availability exceeds the peptide-specific scientific evidence base

10. Pharmacokinetics

No pharmacokinetic studies have been published for isolated Crystagen (EDP). Some indirect pharmacokinetic understanding can be inferred from the parent preparation Thymalin, which has been used clinically via intramuscular injection for over four decades in Russia [2][10].

As a tripeptide of 345 g/mol, EDP faces the same rapid proteolytic degradation as other ultrashort peptides. The proline residue at the C-terminus may confer modest resistance to some carboxypeptidases (proline-containing peptides are generally more protease-resistant than those ending in other amino acids), but this advantage is limited. No plasma half-life, bioavailability, or tissue distribution data have been published for isolated EDP.

For the parent preparation Thymalin (administered intramuscularly at 10 mg), the polypeptide mixture includes EDP among other components. Intramuscular administration bypasses gastrointestinal degradation, providing higher systemic bioavailability than oral dosing. The clinical efficacy observed with injectable Thymalin may not translate to oral EDP capsules, as the pharmacokinetic profiles differ fundamentally -- injectable polypeptide complex versus oral isolated tripeptide.

The proposed target tissues (thymus, spleen, immune cells) are systemically distributed, making systemic delivery via oral or injectable routes theoretically plausible if intact peptide reaches the bloodstream. However, quantitative evidence of intact EDP reaching lymphoid tissue at biologically active concentrations is absent.

11. Dose-Response

No formal dose-response studies have been conducted for isolated Crystagen. The in vitro studies used experimental concentrations (10 to the minus 7 to 10 to the minus 12 M) without systematic dose titration [1][7]. The clinical observational data showing 82% immunogram normalization did not include dose-finding components [2][11].

An indirect dose-response signal exists from the Thymalin clinical data. The standard Thymalin protocol (10 mg IM daily for 5-10 days) was associated with measurable immune reconstitution [2][16], while the oral Crystagen protocol uses 200-400 mcg per day -- approximately 25-50 fold less active substance, delivered via a route with much lower bioavailability. Whether the oral EDP dose achieves sufficient systemic exposure for immune effects is unknown.

The COVID-19 RCT with Thymalin used the standard 10 mg IM protocol and showed significant immune normalization [16]. Extrapolating these results to oral Crystagen capsules requires assumptions about bioequivalence that have not been tested.

12. Comparative Effectiveness

Crystagen (EDP) vs. Thymalin (Extract)

Crystagen is one of three identified active components of Thymalin, alongside Thymogen (EW) and Vilon (KE). Thymalin has the most extensive clinical dataset of any Khavinson preparation, including a COVID-19 RCT and multi-year mortality studies [5][16]. However, its multi-component nature makes it impossible to attribute observed effects to EDP alone. Crystagen may reproduce only a fraction of Thymalin's clinical activity.

Crystagen (EDP) vs. Thymosin Alpha-1

Thymosin alpha-1 (Zadaxin) is a 28-amino acid peptide with approval in 35+ countries, extensive independent RCT data, and well-characterized TLR2/TLR9-mediated immunomodulation. It represents the gold standard for thymic peptide immunotherapy. Crystagen, at 3 amino acids with no independent validation, occupies an entirely different evidence tier. Thymosin alpha-1 has defined pharmacokinetics (subcutaneous bioavailability approximately 100%, half-life approximately 2 hours), while Crystagen has none.

Crystagen (EDP) vs. Thymogen (EW)

Both are Thymalin-derived synthetic peptides. Thymogen (Glu-Trp) has separate Russian regulatory approval and more independent characterization, including defined effects on T-cell differentiation and neutrophil function via cyclic nucleotide modulation [10]. Crystagen appears to have broader effects (both B-cell and T-cell activation) but less independent validation. The two may have complementary rather than redundant mechanisms.

13. Enhanced Safety

Crystagen's safety profile benefits from the long clinical history of its parent preparation Thymalin, which has been described as "practically non-toxic" based on over 40 years of clinical use in Russia [2][10]. In the COVID-19 RCT with Thymalin (which contains EDP), no adverse events were documented in the treatment group [16]. The long-term observational studies (6-8 years, 266 subjects) similarly reported no safety concerns [5].

As a tripeptide of common L-amino acids (glutamic acid, aspartic acid, proline), EDP is expected to be rapidly degraded to its constituent amino acids, which are all abundant in normal metabolism. No genotoxic, cytotoxic, or mutagenic effects have been reported.

The primary safety consideration unique to Crystagen is its immunostimulatory activity. Stimulation of immune cell populations could theoretically worsen autoimmune conditions, accelerate transplant rejection, or produce unpredictable effects during immunotherapy for cancer. No safety data in autoimmune patients, transplant recipients, or individuals receiving immune checkpoint inhibitors exist. The selectivity of Crystagen's effects (stimulating normal lymphocytes while inhibiting K-562 tumor cells [2]) is encouraging but has been demonstrated only in vitro.

No drug interaction studies have been performed. Potential interactions with immunosuppressants (cyclosporine, tacrolimus, mycophenolate), vaccines, biologic immunomodulators, or corticosteroids are entirely unknown.

14. Related Peptides

See also: Thymalin, Thymosin Alpha-1, Epithalon, Chonluten

15. References

1. [1] Chervyakova NA, Linkova NS, Chalisova NI, Koncevaya EA, Trofimova SV, Khavinson VKh. (2017). Molecular aspects of immunoprotective activity of peptides in spleen during the ageing process. Advances in Gerontology (Uspekhi Gerontologii). PubMed
2. [2] Khavinson VKh, Linkova NS, Dyatlova AS, Kuznik BI, Umnov RS. (2021). The use of Thymalin for immunocorrection and molecular aspects of biological activity. Biology Bulletin Reviews. DOI PubMed
3. [3] Kuznik BI, Linkova NS, Khavinson VKh. (2022). Peptides regulating proliferative activity and inflammatory pathways in the monocyte/macrophage THP-1 cell line. International Journal of Molecular Sciences. DOI PubMed
4. [4] Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. (2021). Peptide regulation of gene expression: a systematic review. Molecules. DOI PubMed
5. [5] Khavinson VKh, Morozov VG. (2003). Peptides of pineal gland and thymus prolong human life. Neuro Endocrinology Letters. PubMed
6. [6] Markova EV, Obukhova LA, Khavinson VKh. (2014). Age-related molecular aspects of immunomodulating activity of peptides in the spleen. Advances in Gerontology. DOI
7. [7] Chalisova NI, Linkova NS, Zhekalov AN, Orlova AN, Ryzhak GA, Khavinson VKh. (2006). Tissue-specific effect of synthetic peptide bioregulators in organotypic tissue cultures in young and old rats. Advances in Gerontology (Uspekhi Gerontologii). PubMed
8. [8] Khavinson VKh. (2002). Peptides and ageing. Neuro Endocrinology Letters. PubMed
9. [9] Anisimov VN, Khavinson VKh. (2010). Peptide bioregulation of aging: results and prospects. Biogerontology. DOI PubMed
10. [10] Morozov VG, Khavinson VKh. (1997). Natural and synthetic thymic peptides as therapeutics for immune dysfunction. International Journal of Immunopharmacology. DOI PubMed
11. [11] Khavinson VKh. (2013). Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results. Advances in Gerontology (Uspekhi Gerontologii). PubMed
12. [12] Anisimov VN, Khavinson VKh, Morozov VG. (2000). Immunomodulatory synthetic dipeptide L-Glu-L-Trp slows down aging and inhibits spontaneous carcinogenesis in rats. Biogerontology. DOI PubMed
13. [13] Khavinson VKh, Linkova NS, Kvetnoy IM. (2020). Peptides: prospects for use in the treatment of COVID-19. Molecules. DOI PubMed
14. [14] Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF. (2011). Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Moscow). DOI PubMed
15. [15] Khavinson VKh, Anisimov VN. (2000). Peptide bioregulation of aging: results and prospects. Biogerontology. DOI PubMed
16. [16] Khavinson VKh, Linkova NS, Dyatlova AS. (2021). Peptide drug Thymalin regulates immune status in severe COVID-19 older patients. Advances in Gerontology. DOI PubMed
17. [17] Ashapkin VV, Kutueva LI, Vanyushin BF, Khavinson VKh. (2015). Epigenetic mechanisms of peptidergic regulation of gene expression during aging of human cells. Biochemistry (Moscow). DOI PubMed